Breaking News, Collaborations & Alliances

BioNTech, OncoC4 Partner to Develop mAb Candidate ONC-392 in Cancer

OncoC4 will receive a $200 million upfront and is eligible to receive development, regulatory and commercial milestone payments as well as royalties.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BioNTech SE and OncoC4, Inc., a clinical-stage biopharmaceutical company dedicated to the development of novel biologics for cancer, have entered into an exclusive worldwide license and collaboration agreement to develop and commercialize OncoC4’s next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392, as monotherapy or combination therapy in various cancer indications.    CTLA-4 is a molecule that inhibits the activity of immune cells via various mechanisms. OncoC4’s CTLA-4 antibo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters